1. Type of research {#sec0005}
===================

Foot-and-mouth disease (FMD) is an infectious viral disease that affects cloven-hoofed animals. The causative agent of FMD is foot-and-mouth disease virus (FMDV), which is a positive-sense, single-stranded RNA virus classified in the genus *Aphthovirus* within the family *Picornaviridae.*

There are seven serotypes of FMDV (O, A, Asia 1, C, SAT 1, SAT 2 and SAT 3), each containing multiple genetic lineages. FMDV is not evenly distributed in endemic areas and its distribution can be divided into seven major ecological pools, with each pool containing different variants of the virus that are often restricted to a specific geographical location ([@bib0060]). In Asia, three endemic pools have been identified (Pools 1--3) where serotypes A (lineages: ASIA/G-VII, ASIA/Sea-97, ASIA/Iran-05), O (lineages: ME-SA/Ind-2001, ME-SA/PanAsia-2, SEA/Mya-98, ME-SA/PanAsia, CATHAY) and Asia 1 (lineages: ASIA/Sindh-08, ASIA/G-VIII) co-circulate.

The A/ASIA/G-VII \[also referred to as genotype 18 ([@bib0035])\] lineage is classified within the A serotype, considered to be the most variable of the EurAsian serotypes. In 2015, viruses classified within this lineage were detected in Saudi Arabia, Armenia, Iran and Turkey, and continued to circulate in Saudi Arabia, Turkey and Iran in 2016 and 2017 ([@bib0015]).

The ability to rapidly and accurately characterise FMDV lineages is necessary to understand the epidemiology of field outbreaks, as well as to aid the selection of appropriate vaccines. Lineage-specific real-time RT-PCR assays (rRT-PCR), targeting serotypic determinants encoded within variable VP1 (1D) sequences in the viral capsid, have been shown to be effective tools that can be used to detect and discriminate multiple FMDV lineages ([@bib0010], [@bib0020], [@bib0045], [@bib0050], [@bib0070]). This study describes the development and evaluation of a new A/ASIA/G-VII lineage-specific rRT-PCR assay tailored to specifically detect viruses classified within this lineage.

2. Time required {#sec0010}
================

The time required for this protocol is approximately 3.5 h, comprising of the following:(i)30 min for manual or automated nucleic acid extraction,(ii)30 min for master mix preparation, and(iii)2 h 30 min for amplification of target nucleic acid by one-step real-time RT-PCR.

3. Materials {#sec0015}
============

3.1. Special equipment {#sec0020}
----------------------

Specialised equipment includes the following: Class II biological safety cabinet (e.g. Class II MSC, Walker); PCR instrument (e.g. 7500 Fast Real-Time PCR System, Applied Biosystems); extraction robot − optional (e.g. MagMax Sample Preparation System, ThermoFisher Scientific); and centrifuge (e.g. Heraeus Fresco 21, ThermoFisher Scientific).

3.2. Chemicals and reagents {#sec0025}
---------------------------

Nucleic acid extraction kits: RNeasy MiniKit (Qiagen) for manual extraction or MagMAX- 96 Viral RNA Isolation Kit (ThermoFisher Scientific) for automated extraction; rRT-PCR kit: SuperScriptTM III Platinum^®^ One-Step qRT-PCR System (Invitrogen); A/ASIA/G-VII lineage-specific primers and dual-labelled probe (e.g. Sigma-Aldrich or equivalents) ([Table 1](#tbl0005){ref-type="table"}).Table 1A/ASIA/G-VII specific primers and probes.Table 1Oligo[a](#tblfn0005){ref-type="table-fn"}PositionNucleotide sequence (5′ → 3′)G-VII_FP (sense)465--482TGCTCAACTCCCTGCCTCG-VII_RP (antisense)552--535GAGTTCGGCACGCTTCATG-VII_P (sense)506--524FAM-CCACYACCATCCACGAGCTG-BHQ1[^1]

4. Detailed procedure {#sec0030}
=====================

4.1. Virus samples and preparation {#sec0035}
----------------------------------

A panel of FMDV clinical specimens (original suspensions and fluids; n = 29) and virus isolates (n = 25) was selected from the repository held at the World Reference Laboratory for FMD (WRLFMD) at the Pirbright Institute. FMD viruses in these samples had been previously characterised by VP1 sequencing (Knowles et al., 2016b) to belong to serotype A (lineages: ASIA/G-VII, ASIA/Sea-97, ASIA/Iran-05^SIS−10^, ASIA/Iran-05^FAR−11^), serotype O (lineages: ME-SA/Ind-2001, ME-SA/PanAsia-2^ANT−10^, SEA/Mya-98, CATHAY) and serotype Asia 1 (lineage: ASIA/Sindh-08) ([Table 2](#tbl0010){ref-type="table"}). The panel comprised of: (i) ∼10% (w/v) original suspensions (OS) of vesicular epithelium ([@bib0040]) (n = 23), (ii) original fluid (OF) collected from unruptured vesicles (n = 5), and (iii) FMDV infected bovine thyroid cell culture supernatants (BTy) (n = 25) ([Table 2](#tbl0010){ref-type="table"}).Table 2Diagnostic sensitivity and specificity of the G-VII- specific assay.Table 2Sample nameSerotype/topotypeLineageSample type3DG-VIICt valueCt valueIRN/8/2015A/ASIAG-VIIOS16.4714.57IRN/12/2015A/ASIAG-VIIBTy111.336.73IRN/14/2015A/ASIAG-VIIBTy112.279.11IRN/18/2015A/ASIAG-VIIOS16.2115IRN/21/2015A/ASIAG-VIIBTy112.439.47IRN/1/2016A/ASIAG-VIIBTy19.839.87IRN/8/2016A/ASIAG-VIIBTy111.037.68IRN/11/2016A/ASIAG-VIIBTy111.47.11IRN/11/2016A/ASIAG-VIIOS20.9919.1IRN/12/2016A/ASIAG-VIIBTy111.518.19IRN/20/2016A/ASIAG-VIIBTy111.867.78IRN/23/2016A/ASIAG-VIIOS22.1119.89IRN/39/2016A/ASIAG-VIIBTy116.8715.28IRN/4/2017A/ASIAG-VIIBTy117.2416.3SAU/3/2015A/ASIAG-VIIBTy114.8112.51SAU/4/2015A/ASIAG-VIIOS20.1916.58SAU/8/2015A/ASIAG-VIIBTy114.218.79SAU/9/2015A/ASIAG-VIIBTy112.378.92SAU/14/2015A/ASIAG-VIIBTy119.4416.11SAU/15/2015A/ASIAG-VIIBTy124.7621.47SAU/16/2015A/ASIAG-VIIBTy114.1810.81SAU/17/2015A/ASIAG-VIIBTy115.7410.78SAU/21/2015A/ASIAG-VIIBTy118.6615.14SAU/15/2016A/ASIAG-VIIBTy111.397.83SAU/15/2016A/ASIAG-VIIOS36.3227.96SAU/19/2016A/ASIAG-VIIBTy118.8817.29SAU/20/2016A/ASIAG-VIIBTy118.9816.9SAU/22/2016A/ASIAG-VIIBTy116.8814.67SAU/40/2016A/ASIAG-VIIBTy112.8910.94AFG/5/2013A/ASIAIran-05^FAR−11^OS21.68No CtPAK/31/2015A/ASIAIran-05^FAR−11^OS19.27No CtTUR/31/2014A/ASIAIran-05^SIS−10^OS25.84No CtIRN/9/2015A/ASIAIran-05^SIS−10^OS20.82No CtMAY/15/2014A/ASIASea-97OF29.98No CtVIT/9/2015A/ASIASea-97BTY128.86No CtVIT/10/2015A/ASIASea-97BTY127.63No CtAFG/6/2016Asia 1/ASIASindh-08OS24.83No CtAFG/10/2016Asia 1/ASIASindh-08OS32.39No CtAFG/21/2016Asia 1/ASIASindh-08OS24.5No CtNEP/29/2015O/ME-SAInd-2001dOF26.54No CtMUR/1/2016O/ME-SAInd-2001dOS27.13No CtMUR/3/2016O/ME-SAInd-2001dOF31.58No CtNEP/5/2016O/ME-SAInd-2001dOF34.49No CtAFG/4/2016O/ME-SAPanAsia-2^ANT−10^OS28.65No CtAFG/17/2016O/ME-SAPanAsia-2^ANT−10^OS27.25No CtAFG/19/2016O/ME-SAPanAsia-2^ANT−10^OS25.68No CtHKN/2/2016O/CATHAY--OS31.59No CtHKN/3/2016O/CATHAY--OS30.21No CtHKN/6/2016O/CATHAY--OS33.64No CtHKN/7/2016O/CATHAY--OS36.18No CtMYA/7/2016O/SEAMya-98OS32.02No CtMYA/9/2016O/SEAMya-98OS27.98No CtMYA/10/2016O/SEAMya-98OS30.05No CtTAI/33/2016O/SEAMya-98OF30.71No Ct[^2][^3][^4]

4.2. RNA extraction {#sec0040}
-------------------

All samples were processed in a class II biological safety cabinet and the viral RNA was extracted using either the MagMAX 96 Viral RNA Isolation Kit (automated extraction) or RNeasy MiniKit (manual extraction). For automated extraction, 50 μl sample was mixed with 130 μl prepared lysis buffer supplied as a part of the MagMAX-96 Viral RNA Isolation Kit, while for manual extraction 460 μl sample was mixed with an equal volume of RLT lysis buffer supplied as a part of the RNeasy MiniKit. The viral RNA was stored at −70 °C until used in the experiments.

4.3. Primers and probe {#sec0045}
----------------------

The A/ASIA/G-VII-specific primers and probes were designed following identification of a unique lineage-specific target region in a nucleotide sequence alignment of the VP1 coding region of relevant sequences obtained from GenBank (<http://www.ncbi.nlm.nih.gov/>). All oligonucleotides were synthesised by Sigma-Aldrich (USA), and probes were labelled with BHQ-1 (Black Hole Quencher-1) and FAM at their respective 3′ and 5′ termini ([Table 1](#tbl0005){ref-type="table"}).

4.4. Real-time RT-PCR protocol {#sec0050}
------------------------------

The one-step rRT-PCR was carried out with 5 μl RNA in 25 μl total volume reaction mix containing 2 μl (10 μM) of each primer and 1.5 μl (5 μM) of the probe, 0.5 μl ROX (5 x concentration) 12.5 μl 2 × reaction buffer and 1 μl Superscript III/Platinum Taq enzyme mix (Life Technologies). Amplification conditions were identical to those used for pan-serotypic detection of FMDV ([@bib0065], [@bib0080]): 60 °C for 30 min, 95 °C for 10 min, followed by 50 cycles of 95 °C for 15 s and 60 °C for 1 h. Fluorescence was measured at the end of the 60 °C annealing/extension step. All reactions were performed in duplicate and amplified using the 7500 Fast Real-Time PCR System.

4.5. Protocol evaluation {#sec0055}
------------------------

The initial evaluation of the A/ASIA/G-VII lineage-specific assay was based on the comparison of the rRT-PCR results and the phylogenetic classification based on the VP1 coding sequence ([@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135]), followed by comparison with the results of the 3D pan-serotypic assay ([@bib0030]). All samples were tested in duplicate by the lineage-specific and pan-serotypic rRT-PCRs. The amplification efficiency of the rRT-PCRs was assessed on the basis of a 10-fold dilution series (from 10^−2^ to 10^−7^) of a representative sample belonging to the A/ASIA/G-VII lineage (IRN/12/2015) in a diluent consisting of total nucleic acid extracted from a 10% epithelial suspension prepared from tongue tissue of a healthy cattle. These reactions were performed in duplicate. The rRT-PCR efficiency was calculated by using the following formula: Eff% = 10^−1/slope^ × 100.

5. Results {#sec0060}
==========

5.1. Diagnostic sensitivity and specificity {#sec0065}
-------------------------------------------

Diagnostic specificity and sensitivity of the A/ASIA/G-VII lineage-specific rRT-PCR assay were evaluated with a panel of 54 RNA samples using the pan-serotypic rRT-PCR assay as the reference test ([@bib0030]) ([Table 2](#tbl0010){ref-type="table"}). All samples, previously characterised by phylogenetic analyses of the VP1-coding sequence as belonging to the A/ASIA/G-VII lineage (n = 29), produced a positive rRT-PCR result (a Ct value) for both the lineage-specific and the 3D pan-serotypic rRT-PCR. The Ct values for the A/ASIA/G-VII lineage-specific assay were on average lower by 3.09 (t~1,27~ = 10.1, p = 0.000) than those obtained with the 3D pan-serotypic assay ([Table 2](#tbl0010){ref-type="table"}). In addition, 25 RNA samples representing FMDV lineages other than the A/ASIA/G-VII and circulating in the same geographic area (pools 1 and 3) were tested to evaluate the assay for the diagnostic specificity. All these samples tested positive by pan-serotypic assay (Callahan et al., 2002), but produced no Ct result with the A/ASIA/G-VII-specific assay in each case ([Table 2](#tbl0010){ref-type="table"}).

5.2. Limit of detection {#sec0070}
-----------------------

The relative limit of detection for the A/ASIA/G-VII specific rRT-PCR was assessed by examining ten-fold RNA dilution series of the IRN/12/2015 sample, in duplicate and in parallel with the 3D pan-serotypic assay. The efficiency of the A/ASIA/G-VII-specific assay was calculated to be 103.4%, higher than that obtained for the 3D pan-serotypic assay (97.6%) ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Comparative limit of detection of the A/ASIA/G-VII- and 3D pan-serotypic rRT-PCR assays. RNA dilution series of IRN/12/2015 sample was tested in duplicates with the 3D pan-serotypic assay (○) and the G-VII lineage-specific assay (●).Fig. 1

6. Discussion {#sec0075}
=============

After the emergence of the A/ASIA/G-VII lineage into the Middle East in 2015 ([@bib0025]), the lineage spread rapidly into multiple countries (Saudi Arabia, Armenia, Iran and Turkey) and, despite control efforts, it continues to circulate in this geographical area ([@bib0015] −submitted). Recently, a similar epidemiological event has been reported for the O/ME-SA/Ind-2001d lineage, which also has emerged from the Indian sub-continent and continues to expand its circulation in Asia and the Middle East ([@bib0050], [@bib0075], [@bib0090]). Therefore, there is a need to rapidly and accurately identify samples that contain the A/ASIA/G-VII lineage and to distinguish them from other co-circulating FMDV lineages.

Given that the VP1 coding region varies according to a FMDV serotype and lineage, phylogenetic comparisons of the VP1 coding sequences are routinely used to characterise field viruses for epidemiological purposes ([@bib0005], [@bib0055], [@bib0085]). This knowledge was previously exploited to generate rRT-PCR assays that can detect contemporary FMDV lineages circulating in the Middle East and West Eurasia: O/ME-SA/PanAsia-2, A/ASIA/Iran-05, Asia 1/ASIA/Group1, 2, 6 and 7 ([@bib0045], [@bib0070]), East Africa: A/AFRICA/G-I, O/EA-2, O/EA-4, SAT1/I and SAT2/IV ([@bib0020]), as well as for detection of individual lineages: SAT2/VII and O/ME-SA/Ind-2001 ([@bib0010], [@bib0050]). Expanding the range of tests that are available, this study describes the design and validation of a new A/ASIA/G-VII-specific assay.

This A/ASIA/G-VII-specific rRT-PCR assay was shown to have high diagnostic sensitivity and correctly identified all viruses as belonging to the A/ASIA/G-VII lineage with Ct values lower than those of the pan-serotypic test detecting the 3D coding region. In addition, the genetic material from other FMDV lineages investigated in this study was not amplified, indicating high diagnostic specificity of this assay. Therefore, the application of the A/ASIA/G-VII lineage-specific assay provides a reliable method to rapidly characterise the A/ASIA/G-VII lineage. The G-VII lineage-specific rRT-PCR assay targets the most variable region of the genome making it possible that, with time, the target region will change, altering the assay's specificity and/or sensitivity. Thus, it is important to monitor the performance of the lineage-specific assays over time, and it is recommended that all lineage-specific assays are used in combination with a pan-serotypic diagnostic approach to ensure that the presence of FMDV is correctly identified. The composition and the thermal profile of the G-VII-specific and the 3D pan-serotypic assays ([@bib0080]) were designed to the same specifications, such that both can be performed at the same time and run in parallel using the same PCR cycling instrument.

The application of lineage-specific assays provides a relatively accessible method for FMDV lineage detection to laboratories which do not possess sequencing capacities. The development of this A/ASIA/G-VII-specific assay expands the portfolio (or molecular toolbox) of the published lineage-specific rRT-PCR assays enabling national laboratories in endemic settings to rapidly and accurately characterise this emerging lineage. This can promote rapid and accurate implementing control strategies.

7. Essential literature references {#sec0080}
==================================

(i)[@bib0030](ii)[@bib0080](iii)[@bib0045]

8. Quick procedure {#sec0085}
==================

•For automated RNA extraction, add 50 μl sample (tissue culture supernatant, original fluid or original suspension) to 130 μl MagMAX-96 Viral RNA Isolation Kit Lysis Buffer (ThermoFisher Scientific). Use the MagMAX-96 Viral RNA Isolation Kit (ThermoFisher Scientific) with the MagMAX Sample Preparation System (ThermoFisher Scientific) and follow the manufacturer's protocol.•Alternatively, for manual extraction, add 460 μl sample (tissue culture supernatant, original fluid or original suspension) to 460 μl RNeasy Kit RLT Buffer (Qiagen) and follow manufacturer's protocol.•Use the SuperScript™ III Platinum^®^ One-Step qRT-PCR System (Invitrogen) to prepare the reaction mix with the custom made G-VII-specific primers and probe ([Table 1](#tbl0005){ref-type="table"}) according to the protocol described in Section [4](#sec0030){ref-type="sec"} (Detailed procedure).•Perform rRT-PCR programme as described, time required: maximum 2 h 30 min
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[^1]: Positions according to the VP1 coding sequence of the A/SAU/1/2015 sequence (KU127247).

[^2]: Diagnostic sensitivity tested with samples belonging to the A/ASIA/G-VII lineage (n = 29); diagnostic specificity tested with samples belonging to the A/ASIA/Sea-97 (n = 3), Asia 1/ASIA/Sindh-08 (n = 3), O/CATHAY (n = 4), O/ME-SA/PanAsia-2^ANT−10^ (n = 3), O/ME-SA/Ind-2001d (n = 4), O/SEA/Mya-98 (n = 4), A/ASIA/Iran-05^SIS−10^ (n = 2) and A/ASIA/Iran-05^FAR−11^ (n = 2) lineage.

[^3]: BTy- bovine thyroid cell line; \*OS- original suspension.

[^4]: OF-original fluid; ME-SA- Middle East-South Asia; SEA- South East Asia.
